Search

Your search keyword '"Mehta, Neesurg"' showing total 2 results
Start Over Author "Mehta, Neesurg" Topic macular degeneration
2 results on '"Mehta, Neesurg"'

1. A Case of Suspected nabpaclitaxel-Associated Maculopathy.

Author

Huang D, Mehta NS, Tam KW, Moussa K, and Liu YA

Subjects
Humans, Retinal Diseases chemically induced, Retinal Diseases diagnosis, Macular Degeneration chemically induced, Macular Degeneration diagnosis, Macular Degeneration drug therapy
Abstract

Competing Interests: The authors report no conflicts of interest.

Published
2023
Full Text
View/download PDF

2. Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration.

Author

Mehta, Neesurg, Fong, Rodney D, Wilson, Machelle, Moussa, Kareem, Emami-Naeini, Parisa, Moshiri, Ala, Yiu, Glenn, and Park, Susanna S

Subjects
aflibercept, age-related macular degeneration, anti-VEGF, brolucizumab, intravitreal injection, optical coherence tomography, Clinical Research, Eye Disease and Disorders of Vision, Neurodegenerative, Aging, Macular Degeneration, 6.1 Pharmaceuticals, Development of treatments and therapeutic interventions, 5.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Eye, intravitreal injection, optical coherence tomography, Opthalmology and Optometry
Abstract

PurposeTo evaluate real-world experience using intravitreal brolucizumab (IVBr), alone or in combination with aflibercept, in eyes with neovascular age-related macular degeneration (nAMD) treated previously with other inhibitors of VEGF (anti-VEGF).MethodsThis was a retrospective study of all eyes with nAMD treated with IVBr on a treat-and-extend protocol at a single center. Best-corrected visual acuity (BCVA), optical coherence tomography (OCT) at baseline and final visit, and drug-related adverse events were analyzed. Eyes with recurrent macular fluid on IVBr every 8 weeks were treated with a combination therapy alternating between IVBr and aflibercept every month.ResultsAmong 52 eyes (40 patients) on IVBr, all had been previously treated with other anti-VEGF therapy, with 73% having persistent macular fluid. After a mean follow-up of 46.2±27.4 weeks on IVBr, the mean treatment interval for intravitreal therapy increased to 8.8±2.1 weeks on IVBr from a baseline of 6.1±3.1 weeks (p

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results